Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage.
Stuart J ConnollyMukul SharmaAlexander T CohenAndrew M DemchukAnna CzłonkowskaArne G LindgrenCarlos A MolinaDániel BereczkiDanilo ToniDavid J SeiffgeDavid TanneElse Charlotte SandsetGeorgios K TsivgoulisHanne ChristensenJan Beyer-WestendorfJonathan M CoutinhoMark CrowtherPeter VerhammePierre AmarencoRisto O RoineRobert MikulikRobin LemmensRoland VeltkampSaskia MiddeldorpThompson G RobinsonTruman John MillingVitor Tedim-CruzWilfried LangAnders HimmelmannPer LadenvallMikael KnutssonElla EkholmAndrew LawAmanda TaylorTetyana KaryakinaLizhen XuKate TsiplovaSven PoliBernd KallmünzerChristoph GumbingerAshkan Shoamaneshnull nullPublished in: The New England journal of medicine (2024)
Among patients with intracerebral hemorrhage who were receiving factor Xa inhibitors, andexanet resulted in better control of hematoma expansion than usual care but was associated with thrombotic events, including ischemic stroke. (Funded by Alexion AstraZeneca Rare Disease and others; ANNEXA-I ClinicalTrials.gov number, NCT03661528.).